Acquired Immune Deficiency Syndrome is one of the world's serious health problems. Immune-based therapy
is a new approach in the treatment of HIV infected patients. IMODTM with the ability to correct immune deficiencies has
been introduced for the management of HIV infection. In the phase IV trial study the main objectives were to assess the
possible side effects, evaluate its effect on CD4+ T Lymphocyte count and patients’ and physicians’ satisfactions for 600
HIV infected patients in 13 centers during 2007. The observed adverse events in patients included: headache
and vertigo (1.2%), nausea (1.2%), gastritis (1.2%), phlebitis (1%) and mild rash (1%); serious adverse events
were not observed in any of IMODTM recipients. Therefore it was not needed to terminate the treatment in any
of patient. The results of this study demonstrated that daily prescription of IMODTM significantly increases T
Lymphocyte CD4+ and Total Lymphocyte Count in HIV-positive patients. In addition, nearly 90% of the patients
and 70% physicians are satisfied by IMODTM treatment.
کلید واژگان :
Efficacy, IMODTM, post marketing surveillance, safety, satisfaction, side effect
